Haystack Oncology is based on over two decades of technology and clinical development in the field of liquid biopsy, led by Dr. Bert Vogelstein and his team at Johns Hopkins, who envisioned and pioneered the concept of liquid biopsy approaches for non-invasive cancer screening, detection of minimal residual disease (MRD), and advanced disease therapy monitoring.

Enabling precision oncology to optimize treatment strategies and dramatically improve outcomes for patients with cancer. Haystack Oncology provides best-in-class personalized cancer diagnostics to identify the maximal number of patients with residual, recurrent, and resistant disease who stand to benefit from proactive clinical interventions.